Oesophageal epithelial permeability changes in patients with eosinophilic oesophagitis

Oesophageal epithelial permeability changes in patients with eosinophilic oesophagitis - Oesophageal epithelial permeability changes in EoE

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON36166

Enrollment

Registered

2011-07-19

Start date

2011-09-02

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

idiopathic allergic oesophagitis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Previous diagnosis of eosinophilic oesophagitis confirmed by histopathology e.g. presence of >15 eosinophilic granulocytes per high power field in mid-oesophageal biopsies before the start of any therapy 2. Written informed consent 3. Age 18 * 75 years

Exclusion criteria

Exclusion criteria: 1. Inability to stop topical corticosteroids 2. Inability to stop PPI, H2-receptor antagonist or prokinetic drug for 8 weeks 3. Use of systemic corticosteroids, leukotriene inhibitors, or monoclonal antibodies, in the 2 month period preceding the study 4. Use of oral anticoagulants 5. Use of NSAIDs 6. History of peptic ulcer disease 7. History of Barrett*s oesophagus 8. History of GI cancer 9. History of GI tract surgery (except appendectomy)

Design outcomes

Primary

Measure	Time frame
- Oesophageal intercellular spaces are dilated in EoE patients compared to healthy subjects. - Mucosal permeability to small molecules is increased in EoE patients compared to healthy subjects. - Tissue impedance measurement is affected in EoE patients compared to healthy subjects. - Dilated intercellular spaces correlate with affected tissue impedance and increased mucosal permeability to small molecules in EoE patients. - Affected tissue impedance correlates with increased mucosal permeability to small molecules in EoE patients. - Numbers of oesophageal intraepithelial eosinophils are increased in EoE patients compared to healthy subjects. - Numbers of oesophageal intraepithelial mast cells are increased in EoE patients compared to healthy subjects.	—

Measure

Time frame

- Oesophageal intercellular spaces are dilated in EoE patients compared to healthy subjects. - Mucosal permeability to small molecules is increased in EoE patients compared to healthy subjects. - Tissue impedance measurement is affected in EoE patients compared to healthy subjects. - Dilated intercellular spaces correlate with affected tissue impedance and increased mucosal permeability to small molecules in EoE patients. - Affected tissue impedance correlates with increased mucosal permeability to small molecules in EoE patients. - Numbers of oesophageal intraepithelial eosinophils are increased in EoE patients compared to healthy subjects. - Numbers of oesophageal intraepithelial mast cells are increased in EoE patients compared to healthy subjects.

—

Secondary

Measure	Time frame
- Tissue impedance, dilation of intercellular spaces, increased mucosal permeability to small molecules, and numbers of oesophageal intraepithelial mast cells and eosinophils are reversible by 8 weeks administration of 40 mg esomeprazole twice daily. - The composition of inflammatory cells present in the esophageal biopsies - The number of reflux episodes	—

Countries

Netherlands

Outcome results